Angiographic Characteristics and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study

Cardiovascular Risk and Diseases

Five-Year Cumulative Cardiovascular Health and Clinical Events in Patients With Chronic Kidney Disease: The CRIC Study

J Am Heart Assoc

Cao Q, Bi Y, Alvarado F, Anderson AH, Mills KT, Jaeger BC, Chen J, He J, Bundy JD, CRIC Study Investigators *

doi: 10.1161/JAHA.123.033001

Heart Failure

Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease

ESC Heart Fail

Zahir Anjum D, Bonde AN, Fosbol E, Hartwell Garred C, Gislason G, Elmegaard M, Knigge P, Torp-Pedersen C, Andersson C, Pfeffer MA, Jhund PS, McMurray JJV, Petrie MC, Kober L, Schou M

doi: 10.1002/ehf2.14933

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Cardiovascular Risk and DiseasesTherapy and Intervention

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Lancet

Choi KH, Park YH, Lee JY, Jeong JO, Kim CJ, Yun KH, Lee HC, Chang K, Park MW, Bae JW, Doh JH, Cho BR, Kim HY, Kim W, Kim U, Rha SW, Hong YJ, Lee HJ, Ahn SG, Kim DI, Cho JH, Her SH, Jeon DS, Han SH, Lee JB, Lee CW, Kang D, Lee JM, Park TK, Yang JH, Lee SY, Choi SH, Gwon HC, Song YB, Hahn JY, SMART-CHOICE 3 investigators

doi: 10.1016/S0140-6736(25)00449-0

Heart, Artery and Coronary DiseasesTherapy and Intervention

Influence of Pathophysiological Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes

Circulation

Collet C, Munhoz D, Mizukami T, Sonck J, Matsuo H, Shinke T, Ando H, Ko B, Biscaglia S, Rivero F, Engstrøm T, Arslani K, Leone AM, van Nunen LX, Fearon WF, Christiansen EH, Fournier S, Desta L, Yong A, Adjej J, Escaned J, Nakayama M, Eftekhari A, Zimmermann FM, Sakai K, Storozhenko T, da Costa BR, Campo G, West NEJ, De Potter T, Heggermont W, Buytaert D, Bartunek J, Berry C, Collison D, Johnson T, Amano T, Perera D, Jeremias A, Ali Z, Pijls NHJ, De Bruyne B, Johnson NP

doi: 10.1161/CIRCULATIONAHA.124.069450

Heart, Artery and Coronary Diseases

Body Mass Index and 10-Year Clinical Outcomes After Percutaneous Coronary Intervention-Interaction with Age, Sex, Diabetic Status and Clinical Presentation

J Clin Med

Ndrepepa G, Kufner S, Cassese S, Joner M, Xhepa E, Sager HB, Schunkert H, Kastrati A

doi: 10.3390/jcm14051413

Heart, Artery and Coronary DiseasesTherapy and Intervention

Impact of Society Guidelines on Trends in Use of Newer P2Y(12) Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

J Am Heart Assoc

Mohamed MO, Kontopantelis E, Alasnag M, Abid L, Banerjee A, Sharp ASP, Bourantas C, Sirker A, Curzen N, Mamas MA

doi: 10.1161/JAHA.124.034414

RECOMMENDED

Cardiovascular Risk and DiseasesFurther Publications

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA Cardiol

Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, Caldwell K, Kallend D, Stein EA, LIBERATE-HR Investigators

doi: 10.1001/jamacardio.2024.1659

Heart, Artery and Coronary DiseasesTherapy and Intervention

Association of Age- and Body Mass Index-Stratified High On-Treatment Platelet Reactivity With Coronary Intervention Outcomes in East Asian Patients

J Am Heart Assoc

Cha JJ, Lee SJ, Park JH, Hong SJ, Ahn TH, Chang K, Park Y, Song YB, Ahn SG, Suh JW, Lee SY, Cho JR, Her AY, Jeong YH, Kim HS, Kim MH, Shin ES, Kim BK, Lim DS

doi: 10.1161/JAHA.123.031819

Related content

Five-Year Cumulative Cardiovascular Health and Clinical Events in Patients With Chronic Kidney Disease: The CRIC Study

Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial

Influence of Pathophysiological Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes

Body Mass Index and 10-Year Clinical Outcomes After Percutaneous Coronary Intervention-Interaction with Age, Sex, Diabetic Status and Clinical Presentation

Impact of Society Guidelines on Trends in Use of Newer P2Y(12) Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial

Association of Age- and Body Mass Index-Stratified High On-Treatment Platelet Reactivity With Coronary Intervention Outcomes in East Asian Patients